Nu-Med Plus (NUMD) 10-K 21 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 12, 2014
Document and Entity Information:	'	'
Entity Registrant Name	'Nu-Med Plus, Inc.	'
Document Type	'10-K	'
Document Period End Date	31-Dec-13	'
Amendment Flag	'false	'
Entity Central Index Key	'0001543637	'
Current Fiscal Year End Date	'--12-31	'
Entity Common Stock, Shares Outstanding	'	31,772,346
Entity Public Float	$0	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Well-known Seasoned Issuer	'No	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'FY	'

NuMed_Plus_Inc_A_Development_S

Nu-Med Plus, Inc. (A Development Stage Company) Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets	'	'
Cash	$13,229	$731
Prepaid expenses, current	17,995	55,102
Total current assets	31,224	55,833
Long-term assets	'	'
Property and equipment, net	43,242	17,519
Prepaid expenses, long-term	21,556	37,051
Total long-term assets	64,798	54,570
Total assets	96,022	110,403
Current liabilities	'	'
Accounts payable	116	10,587
Accrued Expense	20,862	7,400
Loan payable, Due on demand	0	38,500
Convertible Promissory Note, Due on demand, net	199,384	100,000
Total current liabilities	220,362	156,487
Stockholders' equity (deficit)	'	'
Preferred stock; $0.001 par value per share; 10,000,000 authorized; no shares issued and outstanding, respectively.	0	0
Common stock; $0.001 par value per share; 90,000,000 authorized; 29,972,346 and 26,804,012 shares issued and outstanding, as of December 31, 2013 and December 31, 2012 respectively.	29,972	26,804
Additional paid-in capital	404,063	193,497
Stock subscription payable	40,300	0
Deficit accumulated during the development stage	-598,675	-266,385
Total stockholders' equity (deficit)	-124,340	-46,084
Total liabilities and stockholders' equity (deficit)	$96,022	$110,403

NuMed_Plus_Inc_Balance_Sheet_P

Nu-Med Plus, Inc. Balance Sheet (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position	'	'
Preferred stock authorized	10,000,000	10,000,000
Preferred stock par value	$0.00	$0.00
Preferred stock issued	0	0
Preferred stock outstanding	0	0
Common stock authorized	90,000,000	90,000,000
Common stock par value	$0.00	$0.00
Common stock issued	29,972,346	26,804,012
Common stock outstanding	29,972,346	26,804,012

NuMed_Plus_Inc_A_Development_S1

Nu-Med Plus, Inc. (A Development Stage Company) Statements of Operations (USD $)	12 Months Ended		26 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Income Statement	'	'	'
Revenue	$0	$0	$0
Operating expenses	'	'	'
General and administrative expense	20,538	13,402	34,217
Payroll expense	49,571	58,270	111,188
Rent expense	16,656	14,492	31,148
Professional and consulting Fees	143,676	170,246	313,921
Depreciation and amortization expense	3,195	1,817	5,031
Total operating expenses	233,636	258,227	495,505
Operating Loss	-233,636	-258,227	-495,505
Other income and expense	'	'	'
Interest income	1	18	19
Interest expense	-98,655	-4,535	-103,189
Total other income and expense	-98,654	-4,517	-103,170
Income tax expense	0	0	0
Net loss	($332,290)	($262,744)	($598,675)
Basic and diluted loss per share	($0.01)	($0.01)	'
Weighted average common shares outstanding - basic and diluted	27,819,829	22,635,331	'

NuMed_Plus_Inc_A_Development_S2

Nu-Med Plus, Inc. (A Development Stage Company) Statements of Stockholders' Equity (Deficit) (USD $)	Preferred Stock	Common stock	Additional Paid-In Capital	Stock Subscription Receivable	Deficit Accumulated During te Development Stage	Total
Stockholders' Equity, beginning balance at Oct. 18, 2011	'	'	'	'	'	'
Common Stock issued to founders, shares	0	13,000,000	0	0	0	13,000,000
Common Stock issued to founder, value	$0	$13,000	$0	($13,000)	$0	$0
Services contributed by officers	0	0	3,347	0	0	3,347
Net loss	0	0	0	0	-3,641	-3,641
Stockholders' Equity, ending balance at Dec. 31, 2011	0	13,000	3,347	-13,000	-3,641	-294
Balance common shares, ending balance at Dec. 31, 2011	0	13,000,000	0	0	0	13,000,000
Balance preferred shares, ending balance at Dec. 31, 2011	0	0	0	0	0	0
Services contributed by officers	'	'	'	'	'	0
Common Stock issued through private placement, shares	0	5,943,500	0	0	0	5,943,500
Common Stock issued through private placement, value	0	5,944	83,209	0	0	89,153
Common Stock issued to contractors, shares	0	7,860,512	0	0	0	7,860,512
Common Stock issued to contractors, value	0	7,860	110,047	0	0	117,907
Costs related to private placement	0	0	-3,106	0	0	-3,106
Net loss	0	0	0	0	-262,744	-262,744
Stockholders' Equity, ending balance at Dec. 31, 2012	0	26,804	193,497	0	-266,385	-46,084
Stock Subscription Payable at Dec. 31, 2012	'	'	'	'	'	0
Balance preferred shares, ending balance at Dec. 31, 2012	0	0	0	0	0	0
Balance common shares, ending balance at Dec. 31, 2012	0	26,804,012	0	0	0	26,804,012
Stock subscription receivable relieved at Dec. 31, 2012	'	'	'	'	'	13,000
Services contributed by officers	0	0	3,184	0	0	3,184
Common Stock issued for loan conversion, shares	0	168,334	0	0	0	168,334
Common Stock issued for loan conversion, value	0	168	50,332	0	0	50,500
Common Stock issued to contractors, shares	0	3,000,000	0	0	0	3,000,000
Common Stock issued to contractors, value	0	3,000	42,000	0	0	45,000
Beneficial conversion feature	0	0	115,050	0	0	115,050
Net loss	0	0	0	0	-332,290	-332,290
Stockholders' Equity, ending balance at Dec. 31, 2013	0	29,972	404,063	0	-598,675	-124,340
Stock Subscription Payable at Dec. 31, 2013	$0	$0	$0	$40,300	$0	$40,300
Balance common shares, ending balance at Dec. 31, 2013	0	29,972,346	0	0	0	29,972,346
Balance preferred shares, ending balance at Dec. 31, 2013	0	0	0	0	0	0

NuMed_Inc_A_Development_Stage_

Nu-Med, Inc. (A Development Stage Company) Statements of Cash Flows (USD $)	12 Months Ended		26 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities:	'	'	'
Net loss	($332,290)	($262,744)	($598,675)
Depreciation	3,195	1,817	5,030
Stock for service	72,602	50,755	123,357
Services rendered for subscription receivable	0	13,000	13,000
Services contributed by officers	3,184	0	6,532
Amortization of the Beneficial Conversion Feature	84,334	0	84,334
Decrease in prepaid expenses	25,000	75,000	100,000
Increase in accounts payable	-10,470	10,587	116
Increase in accrued expense	13,962	7,400	21,362
Net cash used in operating activities	-140,483	-104,185	-244,944
Cash flows from investing activities:	'	'	'
Purchases of property and equipment	-28,919	-18,800	-48,273
Net cash used in investing activities	-28,919	-18,800	-48,273
Cash flows from financing activities	'	'	'
Proceeds from the sale of common stock	40,300	86,046	126,346
Proceeds from loans payable	141,600	38,708	182,008
Payments on loans payable	0	-1,908	-1,908
Net cash provided by financing activities	181,900	122,846	306,446
Net increase(decrease) in cash	12,498	-139	13,229
Cash at beginning of period	731	870	0
Cash at end of period	13,229	731	13,229
Supplemental schedule of cash flow information	'	'	'
Cash paid for interest	0	0	0
Cash paid for income taxes	$0	$0	$0

Organization_and_Description_o

Organization and Description of Business	12 Months Ended
	Dec. 31, 2013
Notes	'
Organization and Description of Business	'
	NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS
	Nu-Med Plus, Inc. is an emerging growth early stage medical device company principally engaged in the design, innovation, development, enhancement and commercialization of beginning, early, and selective later-stage quality medical devices. The Company's immediate focus is on a nitric oxide powder formulation that is 99% pure-with one year shelf life, a "desktop" generator device with controls plus safety monitors built in that delivers inhaled nitric oxide to replace expensive pressurized canisters and a compact mobile rechargeable device to deliver inhaled nitric oxide gas. The Company is incorporated in Utah.
	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	a. Accounting Method
	The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments which are necessary for a fair statement of the results for interim periods have been included.
	b. Revenue Recognition
	The Company is currently developing its products. It is anticipated that revenue will be recognized on product sales once the product has been shipped to the customers, persuasive evidence of an agreement exists, the price is fixed or determinable, and collectability is reasonably assured.
	c. Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
	d. Cash and Cash Equivalents
	The Company considers all deposit accounts and investment accounts with an original maturity of 90 days or less to be cash equivalents.
	e. Fixed Assets
	Fixed assets are stated at cost.  Expenditure for minor repairs, maintenance, and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. Expenditures, exceeding $500, for new assets or that increase the useful life of existing assets are capitalized.  Depreciation is computed using the straight-line method.  The lives over which the fixed assets are depreciated are five to seven years.
	f. Earnings per Share
	The computation of earnings per share of common stock is based on the weighted average number of shares outstanding during the period of the financial statement.
		For the year ended December 31, 2013	For the year ended December 31, 2012
	Net loss (numerator)	$                (332,290)	$                (262,744)
	Shares (denominator)	27,819,829	22,635,331
	Net loss per share amount	$                       (0.01)	$                       (0.01)
	Diluted earnings per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. During the year there were no outstanding common stock equivalents. Furthermore, due to the net loss for the year, common stock equivalents would not be included in the calculation of the net loss per common share, as their inclusion would be anti-dilutive.
	g. Income Taxes
	Deferred taxes are provided on an asset and liability approach whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
	h. Equity Instruments Issued for Non-Cash Items
	In accordance with ASC Topic 718, the Company records equity instruments issued for non-cash items at the grant-date fair value of the equity instruments issued.
	i. Research and Development Costs
	Research and development costs are expenses as incurred.  These costs consist primarily of consulting fees and payroll related costs.  The costs for the years ended December 31, 2013 and 2012 were $66,214 and $22,134, respectively.
	NOTE 3 - GOING CONCERN
	The Company anticipates that the funds on hand as of December 31, 2013, will not be sufficient and funding through the sale of equity capital and short term related party and other shareholder loans in order to meet the planned expenditures for development, operations, and administrative cost over the next 12 months will be required. Planned expenditures are approximately $220,000 for 2014.  The company is funded through February 2014 and are in negotiations with 3 other investors to take the Company through 2014. Management will adjust any salaries and expenditures based on the need for successful continuous operations. If plans to obtain further financing prove to be insufficient to fund operations, continued viability could be at risk. These factors raise substantial doubt about the Company's ability to continue as a going concern.

Fixed_Assets

Fixed Assets	12 Months Ended
	Dec. 31, 2013
Notes	'
Fixed Assets	'
	NOTE 4 - FIXED ASSETS
	Fixed assets and related accumulated depreciation consisted of the following at December 31, 2013, and December 31, 2012:
		31-Dec-13	31-Dec-12
	Computer and office equipment	$         48,273	$         19,354
	Accumulated depreciation	-5,031	-1,835
	Total Fixed Assets	$       43,242	$       17,519
	Depreciation expense for the year ended December 31, 2013 and 2012, was $3,195 and $1,817, respectively.

Preferred_and_Common_Stock

Preferred and Common Stock	12 Months Ended
	Dec. 31, 2013
Notes	'
Preferred and Common Stock	'
	NOTE 5 - PREFERRED STOCK
	On October 19, 2011, the Company filed Articles of Incorporation with the State of Utah so as to authorize 10,000,000 shares of preferred stock having a par value of $0.001 per share. No preferred shares are issued or outstanding at December 31, 2013.
	NOTE 6 - COMMON STOCK
	On October 19, 2011, the company filed Articles of Incorporation with the State of Utah so as to authorize 90,000,000 shares of common stock having a par value of $0.001 per share. Immediately after authorization, 13,000,000 shares of the common stock were issued, at par, to Company's founding members. This issuance also resulted in the recognition of $13,000 stock subscription receivable as of December 31, 2011.
	On June 30, 2012, the $13,000 stock subscription was relieved, in full, in exchange for 2012 compensation paid to the Company's three founding members.
	On January 19, 2012, the Company initiated a private placement through which it received gross proceeds of $87,563 for the issuance, on April 18, 2012, of 5,843,500 common shares valued at $0.015 per share. Stock issuance costs incurred in connection with this private placement totaled $3,006.
	On April 18, 2012, the Company also issued 7,860,512 common shares valued at $0.015 per share for a total value of $117,907 to consultants and contractors for future services to be provided from the date of issuance through April 1, 2016.
	On October 2, 2012, the Company received $1,500 for 100,000 common shares valued at $0.015 per share, issued November 15, 2012.
	On September 2, 2013, the Company issued 3,000,000 common shares valued at $0.015 per share for a total value of $45,000 to a consultant, as compensation, for prior services.
	On October 28, 2013, the Company issued 168,334 common shares valued at $0.30 per share for a total value of $50,500 in exchange for a $50,000 note payable and for $500 in accrued interest.
	In November and December of 2013, the Company received $40,300 for a Stock Subscription Payable, for which common stock is to be issued in 2014, at a value of $0.30 per share.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Notes	'
Commitments and Contingencies	'
	NOTE 7 - COMMITMENTS AND CONTINGENCIES
	Operating Lease Obligations
	The Company leases office space for which it incurred lease payments, on a month to month basis, beginning in February of 2012 for $1,000 per month. The Company also has a one year lease on lab space beginning April 1, 2012 and ending March 31, 2013, with a monthly lease payment of $388.  Pursuant to the lease agreement, at the end of one year, the term is month to month at the same rate of $388 per month.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2013
Notes	'
Related Party Transactions	'
	NOTE 8 - RELATED PARTY TRANSACTIONS
	Contributed Services
	During the year ended December 31, 2013, Company Officers contributed additional services to the Company in the amount of $3,184.  The Company officers received no compensation and have no expectation of compensation for these services, either now or in the future, and waive their rights to any such compensation.
	Compensation of Officers
	In October of 2011, 13,000,000 shares of common stock were issued to the Company's three founding members. The issuance resulted in the recognition of a $13,000 stock subscription receivable as of December 31, 2011. On June 30, 2012, the $13,000 stock subscription was relieved, in full, in exchange for 2012 compensation paid to these founding members.
	Additionally, for 2012 the Company agreed to compensate its Chief Executive Officer $3,600 per month.  Beginning in January 2013 the Company agreed to compensate its CEO $3,550 per month.

Loan_Payable

Loan Payable	12 Months Ended
	Dec. 31, 2013
Notes	'
Loan Payable	'
	NOTE 9 - LOAN PAYABLE
	The Company received proceeds from a loan in the amount of $1,700 during 2011. This loan was due upon demand, had no stated interest rate, and was retired, in full, by payment in the second quarter of 2012. No interest was paid or recognized, during the year, due to the immateriality of such interest.
	The Company received, during the year ended December 31, 2013, additional proceeds from a loan in the amount of $91,600. The Lender has agreed to loan the Company up to $10,000 per month effective September 2012, for up to one year.  This loan was memorialized in writing on September 30, 2013. The loan is considered to be a demand note, with a maturity 30 days from the receipt of demand and the holder may not make demand for payment until six month from the date thereof. On December 31, 2013, the Company accrued additional interest on this note, at a rate of 8.0% in the amount of $8,321 for the year. The total loan balance and accrued interest is $130,100 and $8,727 respectively. The note contains a conversion option. The conversion price is one share for each $0.01 of principal and accrued but unpaid interest of the note subject to a beneficial ownership limitation. That limitation prevents the holder from owning more than 4.9% of the number of shares of the common stock outstanding after conversion. If the holder's ownership has not previously been reduced to less than 4.9% of the number of shares outstanding, then the limitation shall be 9.9%.
	On September 4, 2013 the Company entered into an agreement with a shareholder wherein shareholder would provide financing to the Company for two months at $25,000 per month. The note is due six months from the date it is presented and surrendered to the Company and bears an interest rate of 8.0% per annum. In September and October 2013, the Company received two $25,000 loans for a total of $50,000, and on October 28, 2013, the outstanding balance of $50,000 along with accrued interest of $500 was converted into common stock at a value of $0.30 per share.
	On November 14, 2012, the Company issued a $100,000 convertible promissory note to a consultant as compensation for services provided and to be provided during the period April, 1, 2012, through March 31, 2013. This note is due on demand, bears annual interest at 5.5%, and is convertible into shares of common stock at a conversion price to be agreed upon immediately prior to conversion. On September 27, 2013, the Company amended the note to include the conversion price which is one share for each $0.01 of principle and accrued but unpaid interest of the note. Of the original $100,000, $75,000 had been expensed as part of the professional/consulting fees on the statement of operations during the year ended December 31, 2012, and the remaining $25,000 was expensed ratably using the straight-line method over the last three months in the service period.  On December 31, 2013, the Company has accrued additional interest on this note in the amount of $5,500 for the year ended December 31, 2013. As of December 31, 2013, the company accrued interest on this note in the total amount of $9,629.
	The Company has evaluated these convertible under the provisions of ASC Topic 815 and has concluded that neither of the convertible contains an embedded derivative requiring bifurcation from the host contract. Therefore, we have accounted for the conversion features of these instruments in accordance with ASC Topic 470. Accordingly, we have recognized the value of beneficial conversion features in these instruments as the difference between the conversion price and the fair value of the Company’s common stock on the date of the transaction.  As a result the Company has recognized debt discounts resulting from these beneficial conversion features amounting to $50,000 and $65,050, respectively, for the November 14, 2012 and September 27, 2013 notes.  The value of these discounts is to be accreted to the loans over the remaining contractual lives of the loans.  Accretion recognized as additional interest expense during the periods ended December 31, 2013 and December 31, 2012 was $84,334 and $0, respectively. The ending value of the debt discount as of December 31, 2013 and December 31, 2012 was $30,716 and $0, respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Notes	'
Income Taxes	'
	NOTE 10 – INCOME TAXES
	The provision (benefit) for income taxes for the years ended December 31, 2013, and 2012, consists of the following:
			2013			2012
	Federal:
	Current	$	0	$	0
	Deferred		0		0
	State:
	Current		0		0
	Deferred		0		0
	Total	$	0	$	0
	The income tax provision differs from the amount of income tax determined by applying the U.S. federal and applicable state income tax rates to pretax income from continuing operations for the years ended December 31, 2013, and 2012, due to the following:
				2013		2012
	Book Income		$	-129,600	$	(102,500)
	Depreciation			(200)		-3,600
	Shares issued for services			-25,500		19,800
	Contributed services			1,200		0
	Beneficial Conversion Feature Amortization			32,900		0
	Valuation allowance			121,200		86,300
		Total	$	0	$	0
	Net deferred tax liabilities consist of the following components as of December 31, 2013, and 2012:
				2013		2012
	Deferred tax assets:
		NOL Carryover	$	227,000	$	86,300
	Deferred tax liabilities
		Depreciation		(3,700)		(3,600)
	Valuation allowance			(223,300)		(82,700)
	Net deferred tax asset		$	0	$	0
	Due to the change in ownership provisions of the Tax Reform Act of 1986, net operating loss carryforwards for Federal income tax reporting purposes are subject to annual limitations.  If a change in ownership occurs, then net operating loss carryforwards may be limited as to use in future years.  At December 31, 2013, the Company had net operating loss carryforward of approximately $583,000 that may be offset against future taxable income from the year 2014 through 2031. The availability of some of the net operating loss will extend into 2033 if not previously utilized. During 2013, the Company evaluated its deferred tax assets and concluded that none of the asset is currently realizable and that a full valuation allowance should be recorded.  The valuation allowance increased by $140,600 and leaves the Company with a net deferred tax asset of $0 as of December 31, 2013.
	Included in the balance at December 31, 2013, are no tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility.  Because of the impact of deferred tax accounting, other than interest and penalties, the disallowance of the shorter deductibility period would not affect the annual effective tax rate but would accelerate the payment of cash to the taxing authority to an earlier period.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Notes	'
Subsequent Events	'
	NOTE 11 - SUBSEQUENT EVENTS
	The company has evaluated subsequent events in accordance with ASC topic 855 and has identified the following subsequent events:
	On January 7, 2014, the Company issued 1,800,000 common shares at $0.01 per share to a consultant, as compensation, for current and future services.

Organization_and_Description_o1

Organization and Description of Business (Policies)	12 Months Ended
	Dec. 31, 2013
Policies	'
Accounting Method	'
	a. Accounting Method
	The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments which are necessary for a fair statement of the results for interim periods have been included.
Revenue Recognition	'
	b. Revenue Recognition
	The Company is currently developing its products. It is anticipated that revenue will be recognized on product sales once the product has been shipped to the customers, persuasive evidence of an agreement exists, the price is fixed or determinable, and collectability is reasonably assured.
Estimates	'
	c. Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.  Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	d. Cash and Cash Equivalents
	The Company considers all deposit accounts and investment accounts with an original maturity of 90 days or less to be cash equivalents.
Fixed Assets	'
	e. Fixed Assets
	Fixed assets are stated at cost.  Expenditure for minor repairs, maintenance, and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. Expenditures, exceeding $500, for new assets or that increase the useful life of existing assets are capitalized.  Depreciation is computed using the straight-line method.  The lives over which the fixed assets are depreciated are five to seven years.
Earnings Per Share	'
	f. Earnings per Share
	The computation of earnings per share of common stock is based on the weighted average number of shares outstanding during the period of the financial statement.
		For the year ended December 31, 2013	For the year ended December 31, 2012
	Net loss (numerator)	$                (332,290)	$                (262,744)
	Shares (denominator)	27,819,829	22,635,331
	Net loss per share amount	$                       (0.01)	$                       (0.01)
	Diluted earnings per share is computed using the weighted average number of common shares plus dilutive common share equivalents outstanding during the period. During the year there were no outstanding common stock equivalents. Furthermore, due to the net loss for the year, common stock equivalents would not be included in the calculation of the net loss per common share, as their inclusion would be anti-dilutive.
Income Taxes	'
	g. Income Taxes
	Deferred taxes are provided on an asset and liability approach whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax basis.  Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
H. Equity Instruments Issued For Non-cash Items	'
	h. Equity Instruments Issued for Non-Cash Items
	In accordance with ASC Topic 718, the Company records equity instruments issued for non-cash items at the grant-date fair value of the equity instruments issued.
Research and Development Costs	'
	i. Research and Development Costs
	Research and development costs are expenses as incurred.  These costs consist primarily of consulting fees and payroll related costs.  The costs for the years ended December 31, 2013 and 2012 were $66,214 and $22,134, respectively.
Going Concern	'
	NOTE 3 - GOING CONCERN
	The Company anticipates that the funds on hand as of December 31, 2013, will not be sufficient and funding through the sale of equity capital and short term related party and other shareholder loans in order to meet the planned expenditures for development, operations, and administrative cost over the next 12 months will be required. Planned expenditures are approximately $220,000 for 2014.  The company is funded through February 2014 and are in negotiations with 3 other investors to take the Company through 2014. Management will adjust any salaries and expenditures based on the need for successful continuous operations. If plans to obtain further financing prove to be insufficient to fund operations, continued viability could be at risk. These factors raise substantial doubt about the Company's ability to continue as a going concern.

Organization_and_Description_o2

Organization and Description of Business (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Schedule of Earnings Per Share, Basic and Diluted	'
		For the year ended December 31, 2013	For the year ended December 31, 2012
	Net loss (numerator)	$                (332,290)	$                (262,744)
	Shares (denominator)	27,819,829	22,635,331
	Net loss per share amount	$                       (0.01)	$                       (0.01)

Fixed_Assets_Tables

Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Property, Plant and Equipment	'
		31-Dec-13	31-Dec-12
	Computer and office equipment	$         48,273	$         19,354
	Accumulated depreciation	-5,031	-1,835
	Total Fixed Assets	$       43,242	$       17,519

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Tables/Schedules	'
Schedule of Components of Income Tax Expense (Benefit)	'
			2013			2012
	Federal:
	Current	$	0	$	0
	Deferred		0		0
	State:
	Current		0		0
	Deferred		0		0
	Total	$	0	$	0
Schedule of Effective Income Tax Rate Reconciliation	'
				2013		2012
	Book Income		$	-129,600	$	(102,500)
	Depreciation			(200)		-3,600
	Shares issued for services			-25,500		19,800
	Contributed services			1,200		0
	Beneficial Conversion Feature Amortization			32,900		0
	Valuation allowance			121,200		86,300
		Total	$	0	$	0
Schedule of Deferred Tax Assets and Liabilities	'
				2013		2012
	Deferred tax assets:
		NOL Carryover	$	227,000	$	86,300
	Deferred tax liabilities
		Depreciation		(3,700)		(3,600)
	Valuation allowance			(223,300)		(82,700)
	Net deferred tax asset		$	0	$	0

Organization_and_Description_o3

Organization and Description of Business (Details) (USD $)	3 Months Ended	12 Months Ended		26 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Details	'	'	'	'
Net loss	($3,641)	($332,290)	($262,744)	($598,675)
Weighted average common shares outstanding - basic and diluted	'	27,819,829	22,635,331	'
Basic and diluted loss per share	'	($0.01)	($0.01)	'
Research and Development Expense	'	66,214	22,134	'
Planned expenditures	'	$220,000	'	'

Fixed_Assets_Details

Fixed Assets (Details) (USD $)	12 Months Ended		26 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Details	'	'	'
Property, Plant and Equipment, Gross	$48,273	$19,354	$48,273
Accumulated Depreciation	-5,031	-1,835	-5,031
Property and equipment, net	43,242	17,519	43,242
Depreciation	$3,195	$1,817	$5,030

Preferred_and_Common_Stock_Det

Preferred and Common Stock (Details) (USD $)	3 Months Ended	12 Months Ended			26 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Details	'	'	'	'	'
Preferred stock authorized	'	10,000,000	10,000,000	'	10,000,000
Preferred stock par value	'	$0.00	$0.00	'	$0.00
Common stock authorized	'	90,000,000	90,000,000	'	90,000,000
Common stock par value	'	$0.00	$0.00	'	$0.00
Common stock outstanding	'	29,972,346	26,804,012	13,000,000	29,972,346
Services rendered for subscription receivable	'	$0	$13,000	'	$13,000
Stock subscription receivable relieved	'	'	13,000	13,000	'
Private Placement Amount	'	87,563	'	'	'
Private Placement Shares	'	5,843,500	'	'	'
private placement per share price	'	$0.02	'	'	'
private placement cost	'	3,006	'	'	'
Common Stock issued to contractors, shares	1,800,000	3,000,000	7,860,512	'	'
Common Stock issued to contractors, value	'	45,000	117,907	'	'
Common Stock issued for cash	'	1,500	'	'	'
Common Stock issued for cash, shares	'	100,000	'	'	'
Common Stock issued for loan conversion, shares	'	168,334	'	'	168,334
Debt Instrument, Convertible, Conversion Price	'	0.3	'	'	0.3
Common Stock issued for loan conversion, value	'	50,500	'	'	50,500
Debt Conversion, Original Debt, Amount	'	50,000	'	'	50,000
Debt Conversion Accrued Interest	'	500	'	'	'
Stock subscription payable	'	$40,300	$0	'	$40,300
Stock Subscription Price Per Share	'	$0.30	'	'	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	12 Months Ended
	Dec. 31, 2013
Details	'
monthly office lease payment	$1,000
monthly lab lease payment	$388

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	3 Months Ended	12 Months Ended			26 Months Ended
	Dec. 31, 2011	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013
Details	'	'	'	'	'
Services contributed by officers	$3,347	$3,184	$0	'	$6,532
Common Stock issued to founders, shares	13,000,000	'	'	'	'
Stock subscription receivable relieved	'	'	13,000	13,000	'
Officers' Compensation	'	$3,550	$3,600	'	'

Loan_Payable_Details

Loan Payable (Details) (USD $)	12 Months Ended		26 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2011
Details	'	'	'	'
Loan payable, Due on demand	$0	$38,500	$0	$1,700
Additional Loan Proceeds	91,600	'	91,600	'
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current	'The Lender has agreed to loan the Company up to $10,000 per month effective September 2012, for up to one year	'	'	'
Accounts Payable, Interest-bearing, Interest Rate	8.00%	'	8.00%	'
additional loan accrued interest	8,321	'	'	'
Convertible Notes Payable	130,100	'	130,100	'
convertible note payable accrued interest	8,727	'	'	'
Debt Instrument, Convertible, Terms of Conversion Feature	'The conversion price is one share for each $0.01 of principal and accrued but unpaid interest of the note subject to a beneficial ownership limitation. That limitation prevents the holder from owning more than 4.9% of the number of shares of the common stock outstanding after conversion. If the holder's ownership has not previously been reduced to less than 4.9% of the number of shares outstanding, then the limitation shall be 9.9%.	'	'	'
Shareholder Loan Amount Per Month	25,000	'	25,000	'
Related Party Transaction, Amounts of Transaction	50,000	'	'	'
Debt Conversion, Original Debt, Amount	50,000	'	50,000	'
Debt Conversion Accrued Interest	500	'	'	'
Debt Instrument, Convertible, Conversion Price	0.3	'	0.3	'
Convertible Promissory Note, Due on demand, net	199,384	100,000	199,384	'
Decrease in prepaid expenses	25,000	75,000	100,000	'
Additional Convertible Promissory Note Accrued Interest	5,500	'	'	'
Debt Instrument, Convertible, Interest Expense	9,629	'	'	'
Debt Instrument, Convertible, Beneficial Conversion Feature	65,050	50,000	'	'
Amortization of the Beneficial Conversion Feature	84,334	0	84,334	'
Amortization of Debt Discount (Premium)	$30,716	'	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Details	'	'
Current Federal Tax Expense (Benefit)	$0	'
Deferred Federal Income Tax Expense (Benefit)	0	'
Current State and Local Tax Expense (Benefit)	0	'
Deferred State and Local Income Tax Expense (Benefit)	0	'
Current Income Tax Expense (Benefit)	0	'
Income Tax Expense (Benefit), Continuing Operations	-129,600	-102,500
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation, Amount	-200	-3,600
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount	-25,500	19,800
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount	1,200	0
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amortization, Amount	32,900	0
Valuation Allowance, Deferred Tax Asset, Change in Amount	121,200	86,300
Total	0	0
Deferred Tax Assets, Operating Loss Carryforwards	227,000	86,300
Deferred Tax Liabilities, Other	-3,700	-3,600
Tax Credit Carryforward, Valuation Allowance	-223,300	-82,700
Deferred Tax Assets, Net	0	0
Deferred Tax Assets, Tax Credit Carryforwards	'	583,000
Valuation Allowances and Reserves, Period Increase (Decrease)	$140,600	'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Details	'	'	'
Common Stock issued to contractors, shares	1,800,000	3,000,000	7,860,512
Price per share of shares issued for services	'	$0.01	'